KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Total Non-Current Liabilities (2024 - 2025)

Historic Total Non-Current Liabilities for Recursion Pharmaceuticals (RXRX) over the last 3 years, with Q3 2025 value amounting to $351.5 million.

  • Recursion Pharmaceuticals' Total Non-Current Liabilities rose 7671.02% to $351.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $351.5 million, marking a year-over-year increase of 7671.02%. This contributed to the annual value of $409.1 million for FY2024, which is 11500.97% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Total Non-Current Liabilities of $351.5 million as of Q3 2025, which was up 7671.02% from $381.6 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year Total Non-Current Liabilities high stood at $409.1 million for Q4 2024, and its period low was $188.4 million during Q2 2024.
  • For the 3-year period, Recursion Pharmaceuticals' Total Non-Current Liabilities averaged around $298.1 million, with its median value being $351.5 million (2025).
  • In the last 5 years, Recursion Pharmaceuticals' Total Non-Current Liabilities soared by 11500.97% in 2024 and then surged by 7671.02% in 2025.
  • Over the past 3 years, Recursion Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $190.3 million in 2023, then skyrocketed by 115.01% to $409.1 million in 2024, then dropped by 14.06% to $351.5 million in 2025.
  • Its Total Non-Current Liabilities stands at $351.5 million for Q3 2025, versus $381.6 million for Q2 2025 and $366.5 million for Q1 2025.